Efmarodocokin alfa Completed Phase 2 Trials for COVID-19 Pneumonia / Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04386616A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia